Saturday 17 October 2026
Export LITS’s income statement to Excel — free account
Lite Strategy, Inc.
LITS Healthcare Biotechnology
Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.14
0.06
−5.00%
Follow LITS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
5.34 | 7.92 | 8.06 | 9.47 | |
Current Ratio |
5.74 | 11.53 | 10.04 | 12.39 | |
Net Debt/EBITDA |
0.50 | 0.35 | 0.29 | 2.70 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.09 | 0.06 | 0.06 | 1.24 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.82 | 0.80 | 0.86 | 0.88 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.03) | (0.04) | (0.05) | (0.15) | |
Capex per Share |
0.09 | 0.05 | 0.00 | (3.39) | |
Free Cash Flow per Share |
0.06 | 0.01 | (0.05) | (3.55) | |
Cash per Share |
0.17 | 0.21 | 0.23 | 0.34 | |
Shareholders Equity per Share |
1.20 | 1.59 | 2.19 | 3.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.20 | 1.59 | 2.19 | 3.81 | |
Free Cash Flow |
1.95 | 0.41 | (1.93) | (104.51) | |
Working Capital |
5.07 | 10.02 | 9.83 | 12.17 | |
Capital Expenditures |
3.12 | 1.93 | 0.00 | (100.00) | |
Net Current Asset Value |
5.07 | 10.02 | 9.83 | 12.17 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.22 | 0.22 | 0.46 | 0.74 | |
Average Assets |
30.49 | 39.28 | 53.66 | 70.54 | |
Average Common Equity |
29.28 | 38.19 | 51.97 | 68.57 |
Columns are period end dates · fundamentals updated 30 Sep 2026